Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BCL11B
REST API REST API
Homo sapiens
BCL11B is differentially expressed in 249 experiments: 121 organism parts: thymus, ovary, ... (119 more);, 226 disease states: normal, colon carcinoma, ... (224 more);, 109 cell types 362 cell lines 29 compound treatments and 71 other conditions.
Synonyms hRIT1-alpha, CTIP2, CTIP-2, ZNF856B
Orthologs BCL11B (Gallus gallus)   ENSCING00000002911 (Ciona intestinalis)   Bcl11b (Mus musculus)   BCL11B (Bos taurus)   Bcl11b (Rattus norvegicus)   bcl11ba (Danio rerio)   BCL11B (2 of 2) (Danio rerio)   CG9650 (Drosophila melanogaster)   bcl11b (Xenopus laevis)   BCL11B (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, regulation of lipid metabolic process, intracellular, negative regulation of cell proliferation, negative regulation of apoptosis, metal ion binding, nucleic acid binding, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, nucleus, post-embryonic development, axonogenesis, zinc ion binding, post-embryonic camera-type eye development, central nervous system neuron differentiation, regulation of keratinocyte proliferation, alpha-beta T cell differentiation, epithelial cell morphogenesis, skin development, T cell receptor V(D)J recombination, thymus development, odontogenesis of dentine-containing tooth, keratinocyte development, positive T cell selection, T cell differentiation in thymus, RNA polymerase II core promoter proximal region sequence-specific DNA binding, striatal medium spiny neuron differentiation, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription
UniProt Accession Q9C0K0, D3YTK1
Search EB-eye ENSG00000127152
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (34 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-24147, E-GEOD-5258, E-MTAB-37
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
A549
2
E-GEOD-3202, E-GEOD-6013
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-GEOD-18005
MDA-MB-231
1
2
E-TABM-420, E-MTAB-62, E-GEOD-5823
356 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, ... (47 experiments)

Factor Value U/D Experiments
CD4+ T cell
2
5
E-AFMX-5, E-TABM-145, E-GEOD-16190, E-MEXP-1600, E-MTAB-24, ... (7 experiments)
CD8+ T cell
1
3
E-AFMX-5, E-TABM-145, E-GEOD-6740, E-MTAB-25
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
dermal fibroblast
1
E-MEXP-1216
spheroid recovery
1
E-GEOD-4219
activated B-cell
1
E-MEXP-2360
103 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (60 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
glioblastoma
2
E-GEOD-4290, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
220 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-15205, E-GEOD-5542, E-GEOD-3720, ... (18 experiments)

Factor Value U/D Experiments
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
control - IL-1b
1
E-GEOD-7216
interferon-gamma
1
E-GEOD-5542
TGF
1
1
E-GEOD-15205
CNOT7+CNOT8
1
1
E-MEXP-2218
bacterial endotoxin
1
E-GEOD-3284
23 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-2034, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-22278, E-GEOD-10315, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-MEXP-1648, ... (26 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-26495, E-GEOD-22152, E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-19743, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.359 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM